The most distinctive feature of keloid is the extreme deposition of extracellular matrix, including collagens and proteoglycans. The focus of this study was the proteoglycan versican, which presumably defines keloid volume due to its ability to retain large amounts of water through its component glycosaminoglycans. The excessive deposition of versican in keloids was examined by immunohistochemical analysis, and up-regulation of the versican gene in these lesions by real-time PCR.
Introduction
Keloids occur spontaneously or following minor trauma, expanding beyond the boundaries of the original wound and causing serious functional and cosmetic problems. In people predisposed to keloid development, normal wound healing processes are derailed, leading to an exuberant cellular response that includes excessive extracellular matrix (ECM) production and deposition (Wolfram et al., 2009) .
Our group (Naitoh et al., 2005) as well as others (Smith et al., 2008) determined that ECMs are overexpressed in keloid tissues and cells, respectively, as determined using microarray assays. Recently, we demonstrated that micro-RNA-mediated mechanisms, namely a significant decrease in the level of miR196, was involved in the increased collagen synthesis characteristic of keloids (Kashiyama et al., 2012) . In addition, we showed that in these lesions, elastic fiber formation is disrupted due to the excess amounts of the glycosaminoglycan (GAG) chondroitin sulfate (CS) and dermatan sulfate (DS) (Ikeda et al., 2009) .
Versican is a member of the CS/DS-proteoglycan (PG) family. It is distributed in a variety of soft tissues and participates in cell adhesion, migration, proliferation, differentiation, and cartilage development (Matsumoto et al., 2006; Wu et al., 2005) .
The sulfate or carbonyl moieties that from the long GAG side chains of versican enable it to hold large amounts of water. Since excessive PG deposition contributes significantly to keloid volume, the elimination of these molecules by targeted treatment would significantly contribute to resolving the clinical problems associated with keloid development.
Currently, international clinical recommendations on scar management, including keloids, comprise several treatment modalities (Mustoe et al., 2002) . However, among these, triamcinolone, surgery, radiation, and combination therapy have been shown to actually promote the recurrence of keloids rather than permanently eliminate them (Al-Attar et al., Butler et al., 2008; van de Kar et al., 2007) . The difficulty in developing a successful therapeutic strategy is further complicated by the absence of an appropriate model of keloids, a refractory disorder that is specific to humans. The GAG deposition model of keloids developed in this study was based upon our observation of increased versican transcription in primary cultured keloid cells, as determined in promoter assays. Sponges seeded with these aberrant cells were implanted into the subcutaneous space of nude mice and used to study the inhibitory effect of several compounds.
Of the cytokines and growth factors tested, only IL-1β inhibited versican expression. Thus, this animal model provides an invaluable approach to the development of effective therapies aimed at reducing keloid formation, which can then be tested in human trials.
Furthermore, it can be used to identify the in vivo components that promote ECM formation in these abnormal tissues.
Results

Versican accumulation and up-regulation of the gene in keloids
In a previous study (Ikeda et al., 2009) , we found that the ECM deposited in keloids contains large amount of CS and DS. Microarray assays analyzing these tissues showed that versican and other PGs comprising the ECM were expressed at higher levels than in nonlesional skin (Naitoh et al., 2005) . To confirm that versican is 5 expressed at aberrantly high levels in keloids, we subjected six samples of keloids (K1-K6) to histopathological analysis. Hematoxylin-eosin staining revealed numerous fibrillar collagenous matrices forming a whorled pattern and a central collection of broad, compact, hyalinized, collagenous bundles ( Figure 1a ). The presence of massive amounts of GAGs in these matrices was evidenced by toluidine blue staining ( Figure 1a ). Immunohistochemical analysis with anti-versican antibody demonstrated intense versican deposition in the keloids, but not in nonlesional skin (Figure 1a ). However, there was no difference in hyaluronan accumulation ( Figure 1a ). These observations suggest that versican is a specific marker of keloids.
Alternative splicing produces several versican isoforms, designated V0-V3 (Wu et al., 2005) . Two major versican transcripts, namely the V0 and V1 isoforms, were detected in both normal human skin and in keloids by RT-PCR analysis (data not shown). Real-time PCR analysis of the three keloid-derived RNAs and the three normal skin-derived RNAs revealed substantially higher versican mRNA levels in keloids than in normal skin ( Figure 1b ). Semi-quantitative RT-PCR of the six keloid-derived RNAs (K1-K6) and the RNAs derived from five normal skin samples (N1-N5), showed a similar tendency (data not shown).
Primary cultured cells derived from keloids continue to overexpress PGs
Eight keloid cell lines (KL cells) were established from eight individuals and eight normal fibroblast lines (Fb) were established from another eight. Microarray analysis of the ECM using KL and Fb cell line showed that the former continued to overexpress ECM, and showed up-regulation of three PGs (versican, aggrecan, and lumican) under the culture conditions used (Table 1) ; all three PGs are up-regulated 6 in tissues (Naitoh et al., 2005) .
Up-regulation of versican expression in KL cells
To determine whether versican is specifically up-regulated in primary cultured KL cells, versican mRNA levels were measured. As shown by real-time PCR, the ratio of versican to GAPDH expression in KL cells was 2.54 +/-0.53-fold higher than that in Fb (n=5 for both KL cells and Fb) ( Figure 2a ). Furthermore, we used luciferase reporter assays to examine the activity of the versican promoter region, spanning -559 to +353, in KL cells and Fb. As shown in Figure 2b , luciferase activity was 1.73 +/-0.22-fold higher in KL cells. After confirming that antibody 2B1 specifically bound to versican, we performed dot blot analysis, which showed that KL cells over-produce versican protein (4.71 +/-2.53-fold higher than Fb; Figure 2c ).
Regulation of versican expression
Hypothesizing that a decrease in versican expression would lead to a corresponding reduction in keloid volume, we screened various cytokines, growth factors, and signaling-pathway inhibitors. We carried out a series of studies in which LY294002, SB202190, and PD98059 were used to inhibit the PI3K, p38 MAPK, and ERK pathways, respectively. The results showed that PI3K and p38 MAPK, but not ERK, stimulated versican expression in both KL cells and Fb (Figure 3a ).
Among the growth factors and cytokines tested. The addition of IL-1β to Fb and KL cells reduced versican expression in both, by 49.6 +/-13% and 21.2 +/-3.3%, respectively, compared to the corresponding untreated cells (Figure 3b ). These results are consistent with other 7 studies in which IL-1β reportedly suppressed versican expression in gingival fibroblasts (Qwarnstrom et al., 1993) and in arterial smooth muscle cells (Lemire et al., 2007) . Exogenous IL-1β also suppressed relative promoter activity in Fb and KL cells, as evidenced by a decrease in luciferase activity of 65.8 +/-6.9% and 36.5 +/-10%, respectively ( Figure 3c ).
We then examined whether differences in the expression of IL-1β and IL-1 receptors by KL cells and Fb accounted for the differential response to IL-1β and thus for the up-regulation of versican in KL cells.
ELISA assays showed that the amounts of endogenous IL-1β protein in the conditioned medium of both cell types were below the detectable limit (data not shown). Furthermore, according to real-time PCR, KL cells and Fb contain similar levels of IL-1 receptor mRNA in (data not shown). Finally, the addition of an IL-1receptor antagonist did not affect versican expression, although it completely blocked L-1β-induced versican down-regulation ( Figure 3d ). These results indicate that endogenous IL-1β is not involved in versican gene regulation, under these experimental conditions.
Generation of an ex vivo GAG deposition model in mice
As noted above, keloid formation occurs only in humans and so there is no appropriate animal model. We therefore sought to establish an ex vivo model using the ECM-overproducing KL cells. In a previous study, we found that cartilage could be successfully reconstructed using a collagen sponge as a scaffold for chondroprogenitor cells (Togo et al., 2006) . Accordingly, these sponges, which consist of chemically cross-linked collagen resistant to collagenase digestion in vivo, were used in our ex vivo model. Collagen sponges were seeded with 5 × 10 5 KL 8 cells (KL-SPo) or Fb (Fb-SPo) and then implanted into the subcutaneous space of nude mice (Figure 4a ). After various incubation periods, the KL-SPo and Fb-SPo were removed and weighed. After 1 month the KL-SPos were less translucent ( Figure 4a ) and were significantly heavier than the Fb-SPos (29 mg +/-8.1 mg vs. 17 mg +/-6.9 mg, respectively; Figure 4a ). In contrast, a 3-dimensional in vitro incubation of KL-SPos and Fb-SPos for 1 month did not result in significant weight differences ( Figure 4b ). In sponges incubated subcutaneously for 1 month, hematoxylin-eosin and Alcian-blue staining showed, respectively, that greater amounts of ground substances and GAGs had been deposited in the KL-SPos than in the Fb-SPos (Figure 4c ). Immunostaining evidenced larger amounts of versican but not of hyaluronan (data not shown) in the KL-SPos than in the Fb-SPos (Figure 4d ).
Injections with chondroitinase ABC or IL-1β reduced implant growth
The implants were treated with chondroitinase ABC to determine whether the weight increase in the KL-SPo could be suppressed by removing the CS/DS chains of PGs, including versican. Weekly injections of 0.5 U of chondroitinase ABC for 1 month caused a significant reduction in the weight of KL-SPo (from 26 mg +/-6.7 mg to 14 mg +/-6.8 mg; Figure 5a ). In the KL-SPos, Alcian-blue staining revealed that the chondroitinase ABC injections had substantially reduced GAG deposition (Figure 5b ), while versican immunostaining demonstrated that the enzymatic removal of the CS/DS chains caused significant decrease in the levels of the core proteins of the PGs ( Figure   5b ). These data suggest that versican deposition in the KL-SPos is mediated by CS/DS-chain interactions with other matrix components.
By contrast, the amount of collagen deposition in the injected KL-SPos 9 and uninjected KL-SPos was essentially the same, as shown by Masson-trichrome staining (Figure 5b ).
Since exogenous IL-1β reduced versican expression in vitro, we tested its effect on KL-SPos. Although there were no significant differences in alcian blue staining, Masson-trichrome staining, and versican immunostaining between IL-1β treated and non-treated sponges (data not shown), a significant reduction of weight was achieved with thrice-weekly injections of the cytokine (Figure 5c ).
Discussion
While it is clear that normal wound healing processes are derailed in individuals predisposed to developing keloids, the pathogenic mechanisms of keloids are poorly understood, including those resulting in excess ECM production (Wolfram et al., 2009) . PGs are expressed in large amounts in keloids and, because of their GAG-mediated capacity to retain large amounts of water, are likely to play important roles in determining the volume of these aberrant tissues. We previously reported that the GAGs deposited in keloid tissues mainly consist of CS/DS (Ikeda et al., 2009) . Of the three PGs showing increased expression in keloids, lumican GAGs only carry keratan sulfate chains Because the major glycosaminoglycan found in keloids is chondroitin sulfate (Ikeda et al., 2009) , we ruled out lumican as one of the PGs whose level is increased in keloids. In our earlier study of keloids, we were unable to detect aggrecan expression by northern blotting; thus, we assumed its expressions to be weak in keloid tissue (Naitoh et al., 2005) . Therefore, we focused on versican as the major PG deposited in keloids. 10 Several groups have attempted to generate animal models of keloids (e.g., by implanting tissue piece of human keloid tissue into mice (Polo et al., 1998; Waki et al., 1991) ), however, to date, they have not been widely used (Ramos et al., 2008) . Recently, hypertrophic scar tissue implanted into nude mice was shown to undergo a significant size reduction in response to the direct application of basic fibroblast growth factor (Eto et al., 2011) . However, we preliminarily tried to implant small pieces of keloid tissue into nude mice, but after one month these pieces had undergone various degrees of size reduction, probably due to matrix degradation. It may be that size is a critical factor in the prolonged maintenance of the implanted tissue, which is influenced by the proper distribution of nutrients and/or oxygen from the surrounding tissue. In an earlier study, we succeeded in obtaining cartilage production in the subcutaneous space of nude mice by using a chemically cross-linked collagen sponge seeded with chondroprogenitor cells (Togo et al., 2006) . Accordingly, we speculated that these sponges would be an excellent material for studying the mechanisms of GAG deposition in keloids. Indeed, after one month, the KL-SPos were heavier than the Fb-SPos. This result in turn implied that the efficacy of test compounds in suppressing keloid volume could be estimated simply by weighing the sponges. Another advantage of the collagen sponges is that their elasticity facilitates injection with the various candidate therapeutic compounds. A sponge-like scaffold fabricated from polylactic acid (Chung et al., 2008) was also tested but it did not result in significant versican deposition (data not shown).
One of the aims of this study was to identify compounds that inhibited the growth of the KL-SPos. As TGF-β stimulates versican expression in dermal fibroblasts under in vitro conditions (Kahari et al., 1991) , blockade of the TGF-β signaling pathway may also be a potent candidate keloid treatment modality. Similarly, it would be interesting to 11 examine the effects of PI3K and p38MAPK inhibitors on GAG deposition in our ex vivo system. Down-regulation of versican deposition by IL-1β was observed in KL cells in our ex vivo model. Thus, IL-1β may be of therapeutic interest in keloids. Chondroitinase ABC may also be a potent inhibitor of keloid formation based on its ability to remove GAGs, as demonstrated in our ex vivo model. A reduction in keloid volume would be sufficient to relieve many of the clinical symptoms and cosmetic problems of affected individuals. Chondroitinase ABC is currently being tested in a phase III clinical trial in the USA and Japan for the treatment of interdisc herniation (http://www.seikagaku.co.jp/english/pdf/76.pdf). The results of that trial may be applicable to the treatment of keloids. While, there are currently several treatment modalities for keloids, many are unsatisfactory because they fail to prevent recurrence (Butler et al., 2008) . We developed a simple, reliable ex vivo model of keloids that can be used not only to evaluate novel anti-keloid agents but also to identify the mechanisms underlying the pathogenesis of keloids.
Materials and methods
Keloid samples and primary culture
Keloids are defined as raised, red, and inflexible scar tissue that invades the boundaries of the original wound (Butler et al., 2008) . 
Western and dot blot analysis of versican protein
To collect conditioned medium, 2.0 × 10 5 KL cells or Fb were seeded on 6-well plates. Two days after serum starvation induced by culture in 2 ml of DMEM, conditioned medium was collected and used for western blot and dot blot analysis, which were done as described previously (Isogai et al., 1996; Koyama et al., 2007) . Intensities of dots were calculated using ImageQuant TL (GE Healthcare, Amersham Place, England). The values were expressed as the ratios to cell numbers. 15 Generation of an ex vivo GAG deposition model Collagen sponges were prepared and were implanted into subcutaneous pockets of nude mice as previously reported (Togo et al., 2006) . Before implanting sponges, they were incubated overnight in 10% FBS/DMEM with 5 × 10 5 KL cells or Fb, thus generating KL-SPo and Fb-SPo, respectively. Four weeks after implantation, the KL-SPo and Fb-SPo were removed, weighed, and subjected to histological analysis as follows: after fixation with 10% phosphate-buffered formalin for 24 h at 4°C, the sponges were embedded in paraffin and sliced into 7.0 μm sections, which were either stained with hematoxylin-eosin or Alcian-blue (pH 2.5), or subjected to immunohistochemical analysis. 
Figure legends
